Montreal Children's Hospital, McGill University Health Center
Dogma suggests that immunosuppression increases risks with infection. At the start of pandemic COVID-19 there was a rush by many physicians to isolate patients receiving immunosuppressive therapies, in the form of biological immune response modifiers, and to, in some cases, stop the biological therapies that were being used to treat underlying medical conidtions including autoimmunity. The panedemic is now >10 months old and evidence suggests is likely to continue for the next 6-12 months (conservative estimate). What do we offer these patients? How does our current knowledge regarding the immune response to SARS-CO-V2 inform our decision making moving forward.
This is a case based interactive workshop. Case examples will be used to illustrate clinical reasoning strategies to optimize patient management. Participants are welcome to bring challenging cases to the forum for discussion.
As a result of attending this session, participants will be able to:
08:30 - 10:35
|Plenary - 5||2020 update on allergies in kids|
11:00 - 12:00
|Therapeutic immunocompromise in the age of COVID 19: When is your patient at risk? - Christine McCusker||Therapeutic immunocompromise in the age of COVID 19: When is your patient at risk?|